Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Receivables (2023 - 2024)

AC Immune (ACIU) has disclosed Receivables for 2 consecutive years, with $1.3 million as the latest value for Q4 2024.

  • Quarterly Receivables fell 92.75% to $1.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2024, down 92.75% year-over-year, with the annual reading at $1.3 million for FY2024, 92.75% down from the prior year.
  • Receivables for Q4 2024 was $1.3 million at AC Immune, down from $17.4 million in the prior quarter.
  • The five-year high for Receivables was $17.4 million in Q4 2023, with the low at $1.3 million in Q4 2024.